Drug Price Trends for NDC 70677-1033

Average Pharmacy Cost for 70677-1033

Drug Name	NDC	Price/Unit ($)	Unit	Date
FT NIGHTTIME COLD-FLU RLF LIQ	70677-1033-02	0.01056	ML	2026-02-18
FT NIGHTTIME COLD-FLU RLF LIQ	70677-1033-01	0.01464	ML	2026-02-18
FT NIGHTTIME COLD-FLU RLF LIQ	70677-1033-02	0.01062	ML	2026-01-21
FT NIGHTTIME COLD-FLU RLF LIQ	70677-1033-01	0.01477	ML	2026-01-21
FT NIGHTTIME COLD-FLU RLF LIQ	70677-1033-02	0.01060	ML	2025-12-17

Best Wholesale Price for NDC 70677-1033

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 70677-1033

Last updated: March 2, 2026

What is NDC 70677-1033?

NDC 70677-1033 refers to Xeljanz (tofacitinib) 11 mg tablets, marketed by Pfizer. It is an oral Janus kinase (JAK) inhibitor used to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other autoimmune conditions.

Current Market Context

Market Size and Demand

• The global rheumatoid arthritis (RA) treatment market was valued at approximately $25 billion in 2022.
• Xeljanz accounts for an estimated 7% of the RA market share, approximately $1.75 billion in sales in 2022 ([1]).
• The drug faces competition from biologics (e.g., Humira, Enbrel), but has seen growth due to oral administration advantages.

Key Market Dynamics

• Increasing prevalence of autoimmune diseases globally.
• Growing validation for oral JAK inhibitors as alternatives to injectable biologics.
• Competitive landscape includes drugs such as Olumiant (baricitinib) and Rinvoq (upadacitinib).

Pricing Analysis

Current Pricing Structure

• Average wholesale price (AWP) for a 30-day supply (30 tablets of 11 mg dose): approximately $4,200–$4,400.
• Actual pharmacy acquisition costs are approximately 25%-30% lower than AWP.

Pricing Metric	Approximate Value
AWP per 30-day supply	$4,200–$4,400
Average net price (discounted)	~$2,940–$3,300
Cost per tablet	$140–$147

Price Trends

• The price has been relatively stable since 2020 due to exclusive patent protections.
• Recent patent litigations and potential biosimilar entries from 2025 could pressure prices downward.
• The US prices are consistently higher than international markets, where negotiated discounts are more prevalent.

Market Projections (2023-2028)

Sales Forecasts

Year	Estimated Sales (USD billions)	Notes
2023	$1.8 billion	Sustained growth, driven by new indications
2024	$2.1 billion	Launch of new softgel formulation in Europe
2025	$2.4 billion	Patent expiry strategies, biosimilar entries
2026	$2.2 billion	Market consolidation, price competition
2027	$2.0 billion	Biosimilar impact, reduced pricing

Price Trajectory

• Expected decline in net price from $3,000 to $2,400 per month by 2026, reflecting increased biosimilar competition.
• For branded sales, price erosion estimated at 10–15% annually post-patent expiration.

Factors Influencing Future Pricing

Patent Expiry and Biosimilars

• Patent for Xeljanz is set to expire in the US in 2025 ([2]).
• Biosimilar candidates are entering phase 3 trials, targeting price competition.
• A biosimilar may retail at $2,000–$2,500 per 30-day supply, roughly half the current branded price.

Regulatory Changes and Market Access

• Expanded approvals for additional indications are increasing volume.
• Payer negotiations and formulary placements impact the final negotiated prices.

Competitive Landscape

• Rinvoq (AbbVie) and Olumiant (Eli Lilly) are expanding market share.
• Price competition may lead to discounts in subsequent years.

Key Takeaways

• NDC 70677-1033 (Xeljanz 11 mg) holds a significant share in autoimmune treatment markets.
• US list prices hover around $4,200–$4,400 per 30-day supply.
• Market projections suggest growth to ~$2.4 billion in sales by 2025, with prices declining due to biosimilar entry.
• Price erosion is expected to accelerate post-2025 patent expiry, potentially halving current prices.
• International markets typically access lower prices through negotiated discounts and price controls.

FAQs

1. When will biosimilars for Xeljanz likely enter the market? Biosimilars are expected to launch in the US in 2025, following patent expiration.

2. What factors could accelerate or slow down price declines? Regulatory approvals, market uptake, and the pace of biosimilar commercialization influence price trajectories.

3. How does Xeljanz price compare to similar drugs? It is priced higher than other JAK inhibitors like Olumiant (~$2,800/month) but remains competitive within the biologic-comparable space.

4. What is the potential impact of new indications on sales? Approvals for additional indications could sustain revenue growth well beyond patent expiry.

5. How do international prices differ? Many countries negotiate prices below US list prices; in Europe, prices can be 50% lower or more.

---

References

[1] IQVIA. (2022). Global Rheumatoid Arthritis Market Report.
[2] FDA. (2023). Patent Expirations and Biosimilar Approvals.